Central Council for Research in Siddha (CCRS) invited applications for recruitment to the post of Research Assistant (RA), Senior Research Fellow (SRF), Field Assistant and Other. Interested candidates can appear for walk in interview on 7 December 2017.
Important Dates
• Interview Date – 7 December 2017.
CCRS Vacancy Details
• Research Associate(Siddha) – 1 Post
• Senior Research Fellow– 1 Post
• Tamil Scholar– 1 Post
• DEO– 1 Post
• Siddha Pharmacist – 1 Post
• Field Assistant – 1 Post
Eligibility Criteria for RA, SRF, Field Assistant and Other Posts
Educational Qualification
• Research Associate(Siddha) – M.D(Siddha) preferably in Nanju noolum maruthuva needhi noolum/Gunapadam or any other branches from a CCIM recognized Institution
• Senior Research Fellow– M. Pharm. in Pharmaceutics / M.Sc. Pharmaceutical Chemistry with 2 years experience in relevant field.
• Tamil Scholar– Ph.D. in Tamil, Publications/Books- Not less than 5 Numbers.
• DEO– Any degree from a recognized University; The candidate should be proficient in Typing (Tamil & English)
• Siddha Pharmacist – 12th Class or equivalent qualification with Science subjects from a recognized board or University. Diploma in integrated Pharmacy of two years duration conducted by a recognized board / university / institution with Siddha as one of the subjects or Diploma in Siddha (Pharmacy) of two years duration conducted by a recognized board / university / institution.
• Field Assistant – 10th Class pass or equivalent qualification with Science subjects from a recognized board.
Age Limit for RA, SRF, Field Assistant and Other Posts
• Research Associate(Siddha) – 40 years
• Senior Research Fellow– 35 years
• Tamil Scholar– 40 to 65 years
• DEO– 27 years
• Siddha Pharmacist, Field Assistant – 18-35 years
How to apply for CCRS Recruitment 2017 for RA, SRF, Field Assistant and Other Posts
Interested candidates can appear for walk in interview on 7 December 2017 with necessary documents. No TA/DA will be paid for attending the interview.
Comments
All Comments (0)
Join the conversation